CEPI is a Norweigan association with global partnership between public, private, philanthropic and civil society organizations that aims to develop vaccines to stop future epidemics. CEPI works towards the acceleration of vaccine development against emerging infectious diseases and enabling equitable access to vaccines for people during outbreaks. CEPI was launched in Davos in 2017. CEPI aims to fill gaps in the space between vaccine funding and implementation. CEPI is involved in proof-of-concept and safety testing in humans and the establishment of investigational vaccine stockpiles prior to epidemics. The group funds platform technologies with potential to accelerate the development and manufacturing of vaccines against previously unknown pathogens. CEPI supports and coordinates activities to improve response to epidemics and strengthen capacity in countries at risk and works to advance the regulatory science governing product development.
CEPI’s leadership team works across three offices in Oslo, London and Washington D.C. CEPI is governed primarily by the board of 12 voting members, which includes four investors and eight independent members that represent industry, global health, science, resource mobilization and finance, and five observers. The Scientific Advisory Committee advises decisions such as prioritising pathogens and selecting development partners.
Director of Human Resources
Director of CEPI US
Deputy CEO and Director of People, Planning and Policy
Director of Vaccine Research & Development
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- CureVacA biopharmaceutical company developing prophylactic and therapeutic application of messenger RNA, which can be used to develop vaccines. It was founded in 2000 and is located in Tübingen, Germany.
- Moderna TherapeuticsA biotechnology startup company that develops messenger RNA based therapeutics to treat diseases.